Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million - CTKB News | RalliesCytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million
C
CTKB• Q2 results and full-year guidance
- Cytek posted Q2 2026 revenue of $48.1 million, up 6% year over year.
- GAAP net loss widened to $12.2 million; GAAP operating loss widened to $11.4 million.
- GAAP gross margin rose to 59% from 52%, lifting gross profit 19% to $28.3 million.
- Non-GAAP adjusted EBITDA turned to a loss of $1.5 million from a profit of $1.3 million.
- Raised FY 2026 revenue guidance to $207 million-$212 million; installed base reached 3,933 instruments after adding 142 units in Q2.
AEE
•
